NR1I2 and neoplasm: A variety of different classes of compounds that are able to transcriptionally activate SXR (e.g., anandamide, rexinoids, tamoxifen) have been previously observed to slow the proliferation of breast cancer cell lines and/or slow tumor growth in rodent models of breast cancer [3,4,7,38].